Articles published by Immix Biopharma, Inc.
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
August 28, 2024
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
April 29, 2024
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 07, 2024
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
January 24, 2024
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
November 30, 2023
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
October 16, 2023
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
September 19, 2023
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Via GlobeNewswire
Tickers
IMMX
![](https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.